"A new study will explore the safety and effectiveness of corneal collagen crosslinking (CXL) using Riboflavin/Dextran and Hypotonic Riboflavin in patients with progressive keratoconus and corneal ectasia," according to ContactLenses.co.uk. "The research is being carried out by the Cornea and Laser Eye Institute, with Dr Peter Hersh acting as principal investigator, and the specialists hope it will show how CXL can strengthen the cornea and decrease the progression of keratoconus."
